What is a clinical trial?

A clinical trial is a research study involving human participants designed to evaluate medical interventions — such as drugs, devices, or behavioral strategies. Trials follow a structured protocol and are registered on ClinicalTrials.gov. They progress through phases: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale comparison), and Phase 4 (post-market surveillance).

How do I find clinical trials I'm eligible for?

You can search ClinicalTrials.gov or use ClinicalMetric to filter by condition, phase, or location. Each trial listing includes eligibility criteria such as age range, sex, diagnosis, and prior treatment history. Contact the study team directly or ask your physician to refer you to a relevant trial.

Are clinical trials safe to participate in?

Clinical trials are conducted under strict ethical and regulatory oversight, including IRB approval and FDA regulation in the US. All participants must give informed consent after reviewing potential risks and benefits. Phase 1 trials carry more uncertainty, while Phase 3 trials involve interventions with an established safety profile. Participation is always voluntary and you may withdraw at any time.

What are the phases of clinical trials?

Clinical trials progress through four main phases. Phase 1 tests safety and dosing in a small group (20–80 people). Phase 2 evaluates efficacy and side effects in a larger group (100–300). Phase 3 compares the intervention against standard treatments in thousands of participants. Phase 4 occurs after approval and monitors long-term effects in the general population.

Do participants get paid for joining clinical trials?

Many clinical trials offer compensation for time and travel expenses, though payment structures vary widely by study. Compensation is not intended to be coercive. Some trials also cover treatment costs for participants. Always review the consent form carefully and ask the study coordinator about any financial considerations before enrolling.

Lung Cancer Clinical Trials 2026: Targeted Therapy, Immunotherapy & Early Detection

Medical Notice

This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.

Summary

Lung cancer remains the leading cause of cancer death globally, but outcomes for non-small cell lung cancer (NSCLC) have been transformed over the past decade by targeted therapies and immunotherapy. In 2026, the focus is on overcoming resistance to first-generation targeted drugs, bringing effective therapies to earlier-stage disease, and developing the next generation of KRAS inhibitors for the most common mutation in NSCLC. Hundreds of trials are actively recruiting — knowing your tumor's molecular profile is essential before searching.

Molecular Subtypes and Targeted Therapies

NSCLC is now classified primarily by its molecular driver mutation, not just histology. The most important targets and their current trial landscape:

EGFR mutations (15–20% of NSCLC): Osimertinib is standard first-line for EGFR-mutant NSCLC. Trials are testing combinations with chemotherapy (FLAURA2) and fourth-generation inhibitors for osimertinib-resistant mutations (C797S)
KRAS G12C (13% of NSCLC): Sotorasib and adagrasib are approved. Next-generation KRAS inhibitors (olomorasib, glecirasib) with fewer resistance mechanisms are in Phase 2/3
ALK rearrangements (5%): Lorlatinib (3rd-generation ALK inhibitor) is now standard first-line. Trials focus on resistance and CNS metastases
RET, MET, ROS1, NTRK: All have approved targeted therapies with active trials for next-generation inhibitors

Immunotherapy in 2026

For patients without actionable driver mutations, immunotherapy is central to treatment. Pembrolizumab is standard first-line for PD-L1 ≥50% tumors. Current trials are testing:

Novel checkpoint combinations — anti-TIGIT, anti-LAG-3, anti-TIM-3 in combination with PD-1 inhibitors
Bispecific antibodies targeting both PD-1 and another immune checkpoint simultaneously
Perioperative immunotherapy — giving immunotherapy before and after surgery in resectable NSCLC
Consolidation immunotherapy after chemoradiation in stage III unresectable disease (building on PACIFIC trial)

Small Cell Lung Cancer (SCLC) Trials

SCLC is an aggressive subtype with limited treatment options. The DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine failed in trials, but tarlatamab — a DLL3×CD3 bispecific T cell engager — received FDA accelerated approval in 2024 for relapsed SCLC and is now in Phase 3 first-line trials. Lurbinectedin is approved for relapsed SCLC, and combination trials with immunotherapy are ongoing.

Getting Your Biomarker Results First

For lung cancer trial eligibility, comprehensive molecular profiling is essential before searching. This means: NGS panel (EGFR, KRAS, ALK, ROS1, RET, MET, BRAF, NTRK, HER2), PD-L1 by IHC, and increasingly ctDNA/liquid biopsy. The Lung Cancer Foundation of America's LCFA Clinical Trial Matching Service can help match your molecular profile to recruiting studies.